CMS Francis Lefebvre advises GenSight Biologics on its second fundraising in 2026
Please confirm you are human to start the audio.
GenSight Biologics is a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Its shares are admitted to trading on Euronext Paris.
This new fundraising of €1 million in total, through the issuance of new shares and warrants (pre-financed or not), is intended to finance GenSight Biologics's operating activities and working capital requirements, in addition to revenue from early access programs during the preparation period for the RECOVER Phase III trial.
GenSight Biologics was advised by CMS Francis Lefebvre. The CMS Francis Lefebvre team comprised Bertrand Sénéchal, partner, Pierre Maunand, associate, and Antoine Benoist, legal advisor.
CMS Francis Lefebvre already advised GenSight Biologics on its first 2026 fundraising last March.
